CDX 3379

Drug Profile

CDX 3379

Alternative Names: KTN 3379

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Developer Celldex Therapeutics Inc
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Head and neck cancer; Solid tumours; Thyroid cancer

Most Recent Events

  • 05 Jun 2017 Celldex Therapeutics completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Monotherapy) (NCT02014909)
  • 09 May 2017 Celldex Therapeutics plans a phase II trial for Head and neck cancer (Combination therapy, Second-line therapy or greater, Late-stage disease) (NCT03254927)
  • 29 Nov 2016 Kolltan Pharmaceuticals has been acquired and merged into Celldex Therapeutics Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top